fibroleiomyoma (fibroid, uterine leiomyoma)

From Aaushi
Jump to navigation Jump to search

Introduction

Fibrous leiomyoma, especially occurring in the uterus.

Epidemiology

  • 11 of 64 women > 30 years of age (57 premenopausal) with fibroids*
  • particularly prevalent among black women[11]
    • symptoms often more severe in black women than white women[11]

* small study

Pathology

  • on average fibroids increase 1.2 cm in 2.5 years*
  • variation in growth
  • 1/3 of fibroids may regress*
    • smaller fibroids in older women more likely to regress

Genetics

Clinical manifestations

Radiology

Complications

Management

More general terms

References

  1. Stedman's Medical Dictionary 27th ed, Williams & Wilkins, Baltimore, 1999
  2. Journal Watch 22(16):129, 2002 DeWaay DJ et al Natural history of uterine polyps and leiomyomata. Obstet Gynecol 100:3, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12100797
  3. 3.0 3.1 Journal Watch 23(4):33, 2003 Pron G, Bennett J, Common A, Wall J, Asch M, Sniderman K; Ontario Uterine Fibroid Embolization Collaboration Group. The Ontario Uterine Fibroid Embolization Trial. Part 2. Uterine fibroid reduction and symptom relief after uterine artery embolization for fibroids. Fertil Steril. 2003 Jan;79(1):120-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/12524074
  4. 4.0 4.1 Journal Watch 25(4):34, 2005 Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L; Ontario UFE Collaborative Group. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Obstet Gynecol. 2005 Jan;105(1):67-76. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15625144
  5. 5.0 5.1 Worthington-Kirsch R, Spies JB, Myers ER, Mulgund J, Mauro M, Pron G, Peterson ED, Goodwin S; FIBROID Investigators. The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. Obstet Gynecol. 2005 Jul;106(1):52-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15994617
  6. 6.0 6.1 Medical Knowledge Self Assessment Program (MKSAP) 14, American College of Physicians, Philadelphia 2006
  7. 7.0 7.1 7.2 7.3 Moss JG et al. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG 2011 Apr 12 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21481151 <Internet> http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2011.02952.x/abstract
  8. 8.0 8.1 Donnez J et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012 Feb 2; 366:409. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22296075
    Donnez J et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012 Feb 2; 366:421. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22296076
    Stewart EA. Uterine fibroids and evidence-based medicine-Not an oxymoron. N Engl J Med 2012 Feb 2; 366:471. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22296082
  9. 9.0 9.1 Tropeano G et al. Incidence and risk factors for clinical failure of uterine leiomyoma embolization. Obstet Gynecol 2012 Aug; 120:269. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22825084
  10. 10.0 10.1 10.2 FDA MedWatch. April 17, 2014 Laparoscopic Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication - Use Discouraged Due to Increased Risk in Women With Uterine Fibroids. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm393809.htm
    FDA News Release. Nov 24, 2014 FDA warns against using laparoscopic power morcellators to treat uterine fibroids. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm424435.htm
  11. 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 Stewart EA Uterine Fibroids. N Engl J Med 2015; 372:1646-1655. April 23, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25901428 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcp1411029

Database